The stock of Endo International plc – Ordinary Shares (NASDAQ:ENDP) is a huge mover today! About 11.45 million shares traded hands or 99.48% up from the average. Endo International plc – Ordinary Shares (NASDAQ:ENDP) has declined 46.36% since April 6, 2016 and is downtrending. It has underperformed by 48.31% the S&P500.
The move comes after 6 months negative chart setup for the $3.49 billion company. It was reported on Nov, 8 by Barchart.com. We have $13.14 PT which if reached, will make NASDAQ:ENDP worth $314.10 million less.
Endo International plc – Ordinary Shares (NASDAQ:ENDP) Ratings Coverage
Out of 16 analysts covering Endo International plc (NASDAQ:ENDP), 9 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 56% are positive. Endo International plc has been the topic of 35 analyst reports since August 11, 2015 according to StockzIntelligence Inc. Nomura initiated it with “Buy” rating and $100 target price in Tuesday, September 29 report. On Friday, March 18 the stock rating was downgraded by RBC Capital Markets to “Outperform”. On Monday, June 6 the stock rating was initiated by Goldman Sachs with “Neutral”. Leerink Swann downgraded Endo International plc – Ordinary Shares (NASDAQ:ENDP) on Friday, May 6 to “Market Perform” rating. On Friday, April 29 the stock rating was maintained by Citigroup with “Buy”. The stock has “Equal Weight” rating given by Barclays Capital on Friday, May 6. Leerink Swann maintained the stock with “Outperform” rating in Tuesday, August 11 report. Deutsche Bank initiated the stock with “Buy” rating in Tuesday, September 29 report. The stock of Endo International plc – Ordinary Shares (NASDAQ:ENDP) has “Overweight” rating given on Monday, March 21 by JP Morgan. The firm has “Market Perform” rating by BMO Capital Markets given on Wednesday, June 29.
According to Zacks Investment Research, “Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology. The company also provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland.”
Insitutional Activity: The institutional sentiment increased to 0.95 in Q2 2016. Its up 0.03, from 0.92 in 2016Q1. The ratio is positive, as 76 funds sold all Endo International plc – Ordinary Shares shares owned while 90 reduced positions. 42 funds bought stakes while 115 increased positions. They now own 192.40 million shares or 1.49% more from 189.57 million shares in 2016Q1.
Jpmorgan Chase holds 835,264 shares or 0% of its portfolio. Stoneridge Investment Prtnrs Lc holds 0.74% of its portfolio in Endo International plc – Ordinary Shares (NASDAQ:ENDP) for 319,175 shares. Moreover, Us State Bank De has 0% invested in Endo International plc – Ordinary Shares (NASDAQ:ENDP) for 4,878 shares. Cibc Markets accumulated 0.01% or 14,974 shares. Profund Advsr Llc has 0.02% invested in the company for 23,758 shares. Blackrock Grp last reported 0.01% of its portfolio in the stock. Cubist Systematic Strategies Ltd Liability has 0.01% invested in the company for 15,543 shares. New Mexico Educational Retirement Board has 23,000 shares for 0.02% of their US portfolio. National Bank & Trust Of Montreal Can holds 0% or 117,365 shares in its portfolio. Elk Creek Partners Llc has 0% invested in the company for 11,592 shares. Lombard Odier Asset Management (Switzerland) owns 38,460 shares or 0.08% of their US portfolio. Moreover, Wellington Mngmt Gp Llp has 0% invested in Endo International plc – Ordinary Shares (NASDAQ:ENDP) for 1.13M shares. Td Asset last reported 0% of its portfolio in the stock. Andra Ap holds 0.03% or 66,100 shares in its portfolio. Moreover, Mitsubishi Ufj Secs Hldg Company Ltd has 0.01% invested in Endo International plc – Ordinary Shares (NASDAQ:ENDP) for 340 shares.
More news for Endo International plc – Ordinary Shares (NASDAQ:ENDP) were recently published by: Valuewalk.com, which released: “Endo International plc â€“ Ordinary Shares (ENDP) Collapses Taking Hedge Fund …” on May 06, 2016. Valuewalk.com‘s article titled: “Endo International plc â€“ Ordinary Shares (ENDP) Shares Soar” and published on August 09, 2016 is yet another important article.
ENDP Company Profile
Endo International plc, incorporated on October 31, 2013, is a global specialty pharmaceutical firm focused on developing, manufacturing, marketing and distributing branded and generic pharmaceutical products, as well as over-the-counter medications through its operating companies- Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs and SOMAR. The Companyâ€™s divisions include U.S. Branded Pharmaceuticals, which offer portfolio of branded pharmaceuticals such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, BELBUCA, Fortesta Gel, Testim, Aveed, Supprelin LA, and XIAFLEX; U.S. Generic Pharmaceuticals portfolio consists of tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches, and International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American, South African and world markets. It sells generic products primarily in the United States across multiple therapeutic categories.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.